ARIA
Library/sexual wellness/Bremelanotide

Bremelanotide

FDA Approved✓ WADA Permitted

Vyleesi / PT-141

sexual wellness✓FDA ApprovedMelanocortin-4 receptor agonist

FDA-approved for HSDD in premenopausal women. Works centrally (MC4R), not hormonally — unique mechanism vs PDE5 inhibitors or hormones.

Confidence
92%
Half-Life ~2.7 hours
Cost ~$500/mo
Quick Reference
Routesubcutaneous
MechanismActivates MC4R and MC1R in CNS (nucleus preopticus medialis, hypothalamus) → mod...
SequenceNle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Mol. Weight1025.2 Da
Reviewed2026-07-08

Mechanism of Action

Activates MC4R and MC1R in CNS (nucleus preopticus medialis, hypothalamus) → modulates sexual desire pathways independent of sex hormones.

Dosing Protocol

1.7mg SC via auto-injector, ≥45 min before sexual activity. Max 1 dose/24hrs, 8 doses/month.

Key Studies

2019

RECONNECT Phase 3 trials

PMID 29725998rct
2026

Female sexual dysfunction meta-analysis

PMID 40543759systematic_review

Adverse Effects

Nausea (40%)Flushing (20%)HeadacheInjection site reactionsTransient BP elevationFainting (vasovagal)Skin darkening

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy

Storage

Room temperature. Store in original packaging. Do not refrigerate or freeze the auto-injector.

Clinical Applications

  • ["female_sexual_dysfunction"
  • "sexual_wellness"]